Drug Discovery, Drug Research Editorial
-
The Benefits Of Using GenAI In Drug Discovery And Preclinical Development
1/17/2024
The emergence of generative artificial intelligence (GenAI) has the potential to reform early-stage drug discovery and development. Large language models are being harnessed to create novel molecules tailored for specific properties, positioning them as potential drug candidates. It could also unveil previously overlooked therapeutic possibilities. Pharma leaders must ensure they have a sound strategy for this.
-
Reinventing The Classic Pharma Campus
1/15/2024
Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.
-
Oligonucleotides Outsourcing In 2024
12/26/2023
2023, among other potential designations, was the year of oligonucleotides. Accordingly, here’s a question I raised with professionals throughout the year: How do you successfully outsource development and manufacture of an oligo program?
-
Will 2024 Unlock Options Enabling Our Technologies
12/20/2023
Our Advisory Board members describe their outsourcing experiences during 2023, and offer us ideas and questions on how to make 2004 a better environment, specifically for all our advancing platforms.
-
AI's Role In Drug Discovery To Propel Personalized, Patient-Centric Medicine
12/20/2023
AI-driven drug discovery and development represents a future where new medicines could become more precise and effective, better tolerated, and better tailored to an individual. This article shares an overview of how AI can help in this, and how can we work in a more active way toward this future.
-
Best Practices For Preformulation In Drug Development
12/14/2023
Preformulation testing encompasses all studies performed on a new drug compound in order to produce useful information for subsequent formulation of a suitable drug dosage form. There is preformulation across the stages of drug discovery, early development, and late development. The route of administration dictates what is important.
-
How To ID The Best CDMOs
12/13/2023
It takes a certain, trained perspicuity to identify the CDMO right for you. If you are a small biotech, says CEO Matthias Schroff, you most likely will not have the weight to ensure an external partner’s “real focus on producing for you.” Here's what he recommends.
-
Pacesetters Are Product Innovators Who Embrace Digital Process Enhancement
12/12/2023
The Josh Bersin Company recently underwent research examining pharma/biotech “pacesetters” in the field. We caught up with Jordan Schmitting, senior research analyst at The Josh Bersin Company, to discuss the trends illuminated by the research.
-
5 Leadership Learnings In Preventative Cancer Vaccine Development
12/6/2023
Calviri has been developing an RNA vaccine to prevent cancer for more than 20 years and repeatedly faced the nearly universal belief that it’s impossible. We’ve learned a number of important lessons along the way that are worth imparting to other vaccine developers.
-
The RNA Therapeutics Race: How Can Pharma Stay Ahead Of The Wave?
12/5/2023
With more than 970 RNA therapies currently in the development pipeline, the market presents an exciting prospect. This article shares the key attributes of RNA therapies that are paving the way for personalized medicine, novel delivery mechanisms, and more.